Treating kidney cancer spots after immunotherapy
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether directly treating all remaining kidney cancer spots (with surgery, radiation, or other methods) after immunotherapy can help control the disease. It is for people with clear cell kidney cancer that has spread to 5 or fewer places and is not growing on immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of kidney cancer called clear cell renal cell carcinoma (or mixed with clear cells).
- You have 5 or fewer metastases (spots where cancer has spread), not counting tiny lung spots smaller than 1 cm.
- Your cancer has been stable or partly shrunk after at least 6 months of immunotherapy (a checkpoint blocker drug).
- A team of doctors decides that all your cancer spots can be treated directly (with surgery, radiation, or ablation).
- You are able to do daily activities without major help (ECOG score 0 or 1).
- You have a stored tissue sample from before your current treatment for comparison.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted radiation therapy with a restart of immunotherapy for people whose kidney cancer has grown after prior immunotherapy. It aims to see if radiation can help the immune system fight the cancer again.
This study looks at whether people with metastatic kidney cancer can be managed with standard immune-based treatment and then have their main kidney tumor removed. It is meant for people who can have surgery and whose cancer has not grown at the time this approach is considered.
This trial compares standard systemic therapy (medication) alone versus systemic therapy plus targeted radiation to the cancer spots for people with kidney cancer that has spread to a limited number of places (up to 5 spots). It aims to see if adding radiation helps control the cancer better.
This trial tests whether removing or burning (ablating) the main kidney tumor helps people with advanced kidney cancer who are already doing well on immunotherapy. Researchers want to see if combining local treatment with ongoing immunotherapy can improve outcomes.
This trial tests whether adding a special type of radiation to your current immunotherapy can help shrink kidney cancer tumors that have stopped responding or are stable. The goal is to see if the radiation can boost the immune system's ability to fight cancer elsewhere in the body.
This trial tests whether starting immunotherapy (a type of medicine that helps your immune system fight cancer) right away, and delaying surgery to remove the kidney tumor, is a safe and effective approach for people with advanced kidney cancer that has spread. It may help you avoid or delay surgery while still controlling the cancer.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.